SUMICHEMSumitomo Chemical India Limited
Metals · Agricultural Inputs · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Sumitomo Chemical India Limited engages in the manufacture and sale of household and public health insecticides, agricultural pesticides, and animal nutrition products in India and internationally. It also offers crop protection products, such as insecticides, herbicides, fungicides, and miticides; animal nutrition; plant nutrition and plant growth regulators; fumigants and rodenticides; weedicides; and biological products. The company was incorporated in 2000 and is headquartered in Mumbai, India. Sumitomo Chemical India Limited is a subsidiary of Sumitomo Chemical Company Limited.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on SUMICHEM — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Overall evidence is weak (AlgoScore 37/100)
- • Revenue growth: 0.6% YoY
- • Valuation vs sector: P/E 30.6 vs sector 18.2
- • RSI: 15
- • MACD: bearish
Bull case
- • Profit growth: 20.4% YoY
- • ROCE: 19.1%
- • Debt/Equity: 0.02
- • Golden cross setup: SMA50 above SMA200
Bear case
- • Revenue growth: 0.6% YoY
- • Valuation vs sector: P/E 30.6 vs sector 18.2
- • RSI: 15
- • MACD: bearish
Key risks
- • Momentum is fading versus the broader market
- • Revenue growth: 0.6% YoY
- • Valuation vs sector: P/E 30.6 vs sector 18.2
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹14.78). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.